Recent scandals at United and Toshiba are sending off a warning signal about corporate ethics, says former Medtronic CEO Bill George.» Read More
The Lightning Round is extended in this CNBC.com exclusive feature.
Boston Scientific has rallied back to its highest levels since last year's financial crisis and is scheduled to discuss a key defibrillator trial this morning, prompting one large investor to position for a potential decline.
Author Matthew May lays down the gauntlet with this beautiful challenge, "Savvy innovators understand that what isn’t there can often trump what is there."
The market traded sideways on Tuesday with Dow finishing slightly lower and the S&P 500 closing a little higher.
Russia's RTS Index was the first global index to hit the correction stage (down 23 percent since hitting its recent high on June 2nd), but now the MSCI Emerging Markets Index (EEM in its ETF form) is also down double-digits since hitting its recent high on June 1st.
Medtronic said on Wednesday that it had paid nearly $800,000 over an eight-year period to a former military surgeon who has been accused by the Army of falsifying a medical journal study involving one of the company’s products.
Medtronic spokesman Steve Cragle sent CNBC this clarification to Mr. Hawkins' answer to Mike Huckman's question regarding the Senate investigation into a doctor who has done consulting work for MDT.
Medtronic may have set a record. The world's biggest medical device maker put out six press releases this morning.
Futures dropped as housing starts for April came in at 458,000, well below expectations of 520,000, and permits came in at 494,000, also well below expectations of 530,000. However, most of the drop is attributable to lower multifamily construction; single family starts and permits rose, though they are still low.
How does a five-star fund manager approach investing when uncertainty is high? “Every recession we’ve had has ended and this one will end as well,” said Robert Zagunis, 5-star portfolio manager at Jensen Investment Management.
This takes the prize for the most dangerously optimistic acronym for a clinical trial. But MADIT (pronounced "made it") made it. Some folks with a lot of chutzpah at Guidant, now owned by Boston Scientific, apparently came up with the name for their big studies on implantable cardio defibrillators.
The recession is likely to continue throughout the year, but valuations for stocks are looking attractive right now, said Jack Liebau, president and portfolio manager at Liebau Asset Management.
Plus, Cramer makes the call on retail, health care and more.
Following are the day’s biggest winners and losers. Find out why shares of eBay and General Motors popped while ConocoPhillips and Steel Dynamics dropped.
The president’s more concerned with retribution than recovery, Cramer says.
Amid the gloom, Birinyi Associates' Cleve Rueckert found what he sees as a bright spot in the stock market. In a note, he says growth is the place to be, based on performance of the S&P's Pure Growth Index versus the S&P Pure Value Index. Here's his list of 15 stocks in the S&P 500 that fit three key growth criteria.
The Dow and S&P slumped to 11-year lows on Monday as investors lost faith that the U.S. government will be able to stabilize the financial system.
The Dow slid within striking distance of its bear-market low on Tuesday, despite the fact that President Obama signed the economic stimulus into law. What went wrong?
This company has heart, Cramer says. Find out how BSX fought its way off the operating table.
Rob Morgan of Clermont Wealth Strategies got some encouragement from President Obama's remarks about stimulus and recovery, but not enough to make him bullish on financials. That's not to say he's completely down on stocks.